Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02210559 · ClinicalTrials.gov registry record · Phase 1
A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 1 study, sponsored by Kyntra Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT02210559 is a Phase 1 study that has completed, run by Kyntra Bio. The registered enrollment target is 37 participants.
The verdict
NCT02210559, a Phase 1 study, has completed, sponsored by Kyntra Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
This is a Phase 1/2 trial to evaluate the safety, tolerability, and efficacy of FG-3019 administered with gemcitabine and nab-paclitaxel in the treatment of locally advanced, unresectable pancreatic cancer.
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG FG-3019
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2014-07-31 |
| Est. Completion | 2021-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02210559
The ClinicalTrials.gov registry entry for NCT02210559 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT02210559 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02210559 about?
NCT02210559 is a clinical study titled "A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer". This is a Phase 1/2 trial to evaluate the safety, tolerability, and efficacy of FG-3019 administered with gemcitabine and nab-paclitaxel in the treatment of locally advanced, unresectable pancreatic cancer.
What is the current status of trial NCT02210559?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2014-07-31. Estimated completion is 2021-12-15.
What interventions are being tested in trial NCT02210559?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), FG-3019 (DRUG).
Who is sponsoring clinical trial NCT02210559?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.